LENALIDOMIDE IN RELAPSED REFRACTORY MYELOMA PATIENTS: IMPACT OF PREVIOUS RESPONSE TO BORTEZOMIB AND THALIDOMIDE ON TREATMENT EFFICACY. RESULTS OF A MEDICAL NEED PROGRAM IN BELGIUM

被引:4
作者
Delforge, M. [1 ]
Michiels, A. [1 ]
Doyen, C. [2 ]
Kentos, A. [3 ]
Van Droogenbroeck, J. [4 ]
Offner, F. [5 ]
Bries, G. [6 ]
Demuynck, H. [7 ]
Vekemans, M. C. [8 ]
Meuleman, N. [9 ]
Mineur, P. [10 ]
Ravoet, C. [11 ]
Depryck, B. [12 ]
Van de Velde, A. [13 ]
Pierre, P. [14 ]
Wu, K. L. [15 ]
Schots, R. [16 ]
机构
[1] Univ Hosp Gasthuisberg, Afdeling Hematol, Louvain, Belgium
[2] UCL Mt Godinne, Dept Hematol, Yvoir, Belgium
[3] Free Univ Brussels, Hop Erasme, Clin Hematol, B-1070 Brussels, Belgium
[4] AZ Sint Jan Brugge, Afdeling Hematol, Brugge, Belgium
[5] UZ Gent, Afdeling Hematol, Ghent, Belgium
[6] AZ Turnhout, Afdeling Hematol, Turnhout, Germany
[7] Heilig Hart Ziekenhuis, Afdeling Hematol, Roeselare, Belgium
[8] UCL St Luc, Dept Hematol, Brussels, Belgium
[9] Inst Jules Bordet, Dept Hematol, B-1000 Brussels, Belgium
[10] Clin St Joseph, Dept Hematol, Gilly, Switzerland
[11] Hosp Jolimont, Dept Hematol, Jolimont, WA, Belgium
[12] CHR Citadelle, Dept Hematol, Liege, Belgium
[13] UZ Antwerpen, Afdeling Hematol, Edegem, Belgium
[14] Clin Sud Luxembourg, Dept Hematol, Arlon, Luxembourg
[15] ZNA Stuivenbergziekenhuis, Afdeling Hematol, Antwerp, Belgium
[16] UZ Brussel, Afdeling Hematol, Brussels, Belgium
关键词
lenalidomide; multiple myeloma; bortezomib; thalidomide; PLUS DEXAMETHASONE; MULTIPLE-MYELOMA; THERAPY; COMBINATION; PHASE-2;
D O I
10.2143/ACB.66.5.2062589
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The prognosis of multiple myeloma patients has significantly improved since the introduction of the novel agents thalidomide, bortezomib and lenalidomide. We report the data of a medical need programme with lenalidomide plus dexamethasone, conducted in Belgium between August 2007 and March 2008, and including 98 relapsed refractory multiple myeloma patients. In addition to chemotherapy and steroids, all patients had received prior treatment with bortezomib, and 84% of them had been exposed to thalidomide. In 52 patients response data could be retrieved by post-hoc analysis. A partial remission or better was achieved in 52% (49% partial and 3% complete response) of patients, despite a median of 5 previous anti-myeloma treatment lines. Responses were rapid while the majority of patients received lenalidomide with once weekly (also called low-dose) dexamethasone. Treatment with lenalidomide plus dexamethasone did prolong overall survival by nearly half a year in this population with end-stage myeloma. Overall response and quality of response were independent of previous response to thalidomide and bortezomib, although the time to progression tended to be shorter in thalidomide- and bortezomib-refractory patients. It can be concluded that lenalidomide plus dexamethasone is an effective and safe treatment regimen in highly refractory multiple myeloma patients, and that these responses are irrespective of previous exposure or sensitivity to thalidomide and bortezomib.
引用
收藏
页码:371 / 375
页数:5
相关论文
共 15 条
  • [1] Blade Joan, 1998, British Journal of Haematology, V102, P1115, DOI 10.1046/j.1365-2141.1998.00930.x
  • [2] Expanded safety experience with lenalidomide plus dexamethasone in relapsed or refractory multiple myeloma
    Chen, Christine
    Reece, Donna E.
    Siegel, David
    Niesvizky, Ruben
    Boccia, Ralph V.
    Stadtmauer, Edward A.
    Abonour, Rafat
    Richardson, Paul
    Matous, Jeffrey
    Kumar, Shaji
    Bahlis, Nizar J.
    Alsina, Melissa
    Vescio, Robert
    Coutre, Steven E.
    Pietronigro, Dennis
    Knight, Robert D.
    Zeldis, Jerome B.
    Rajkumar, Vincent
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 2009, 146 (02) : 164 - 170
  • [3] Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma
    Dimopoulos, Meletios
    Spencer, Andrew
    Attal, Michael
    Prince, H. Miles
    Harousseau, Jean-Luc
    Dmoszynska, Anna
    San Miguel, Jesus
    Hellmann, Andrzej
    Facon, Thierry
    Foa, Robin
    Corso, Alessandro
    Masliak, Zvenyslava
    Olesnyckyj, Marta
    Yu, Zhinuan
    Patin, John
    Zeldis, Jerome B.
    Knight, Robert D.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2007, 357 (21) : 2123 - 2132
  • [4] International uniform response criteria for multiple myeloma
    Durie, B. G. M.
    Harousseau, J-L
    Miguel, J. S.
    Blade, J.
    Barlogie, B.
    Anderson, K.
    Gertz, M.
    Dimopoulos, M.
    Westin, J.
    Sonneveld, P.
    Ludwig, H.
    Gahrton, G.
    Beksac, M.
    Crowley, J.
    Belch, A.
    Boccadaro, M.
    Turesson, I.
    Joshua, D.
    Vesole, D.
    Kyle, R.
    Alexanian, R.
    Tricot, G.
    Attal, M.
    Merlini, G.
    Powles, R.
    Richardson, P.
    Shimizu, K.
    Tosi, P.
    Morgan, G.
    Rajkumar, S. V.
    [J]. LEUKEMIA, 2006, 20 (09) : 1467 - 1473
  • [5] Analysis of Efficacy and Prognostic Factors of Lenalidomide Treatment as Part of a Dutch Compassionate Use Program
    Kneppers, Evelien
    Lokhorst, Henk M.
    Eeltink, Corien M.
    Huls, Gerwin
    Kersten, Marie Jose
    Koedam, Jan
    Minnema, Monique C.
    van Oers, Marinus H. J.
    Raymakers, Reinier A. P.
    Schaafsma, Martijn R.
    Vellenga, Edo
    Wijermans, Pierre W.
    Wittebol, Shulamiet
    Sonneveld, Pieter
    Zweegman, Sonja
    [J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2010, 10 (02) : 138 - 143
  • [6] Multiple myeloma
    Kyle, Robert A.
    Rajkumar, S. Vincent
    [J]. BLOOD, 2008, 111 (06) : 2962 - 2972
  • [7] Melphalan, prednisone, and lenalidomide treatment for newly diagnosed myeloma:: A report from the GIMEMA -: Italian multiple myeloma network
    Palumbo, Antonio
    Falco, Patrizia
    Corradini, Paolo
    Falcone, Antonietta
    Di Raimondo, Francesco
    Giuliani, Nicola
    Crippa, Claudia
    Ciccone, Giovannino
    Omede, Paola
    Ambrosini, Maria Teresa
    Gay, Francesca
    Bringhen, Sara
    Musto, Pellegrino
    Foa, Robin
    Knight, Robert
    Zeldis, Jerome B.
    Boccadoro, Mario
    Petrucci, Maria Teresa
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (28) : 4459 - 4465
  • [8] Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial
    Rajkumar, S. Vincent
    Jacobus, Susanna
    Callander, Natalie S.
    Fonseca, Rafael
    Vesole, David H.
    Williams, Michael E.
    Abonour, Rafat
    Siegel, David S.
    Katz, Michael
    Greipp, Philip R.
    [J]. LANCET ONCOLOGY, 2010, 11 (01) : 29 - 37
  • [9] A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma
    Richardson, Paul G.
    Blood, Emily
    Mitsiades, Constantine S.
    Jagannath, Sundar
    Zeldenrust, Steven R.
    Alsina, Melissa
    Schlossman, Robert L.
    Rajkumar, S. Vincent
    Desikan, K. Raman
    Hideshima, Teru
    Munshi, Nikhil C.
    Kelly-Colson, Kathleen
    Doss, Deborah
    McKenney, Mary L.
    Gorelik, Svetlana
    Warren, Diane
    Freeman, Andrea
    Rich, Rebecca
    Wu, Anfang
    Olesnyckyj, Marta
    Wride, Kenton
    Dalton, William S.
    Zeldis, Jerome
    Knight, Robert
    Weller, Edie
    Anderson, Kenneth C.
    [J]. BLOOD, 2006, 108 (10) : 3458 - 3464
  • [10] Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma
    Richardson, Paul G.
    Weller, Edie
    Lonial, Sagar
    Jakubowiak, Andrzej J.
    Jagannath, Sundar
    Raje, Noopur S.
    Avigan, David E.
    Xie, Wanling
    Ghobrial, Irene M.
    Schlossman, Robert L.
    Mazumder, Amitabha
    Munshi, Nikhil C.
    Vesole, David H.
    Joyce, Robin
    Kaufman, Jonathan L.
    Doss, Deborah
    Warren, Diane L.
    Lunde, Laura E.
    Kaster, Sarah
    DeLaney, Carol
    Hideshima, Teru
    Mitsiades, Constantine S.
    Knight, Robert
    Esseltine, Dixie-Lee
    Anderson, Kenneth C.
    [J]. BLOOD, 2010, 116 (05) : 679 - 686